The Retatrutide You're Seeing Online Isn't Real. Here's What You Need to Know.
If you've been following the weight loss medication space, you've probably heard the buzz around retatrutide. Developed by Eli Lilly, this investigational drug has generated major excitement thanks to clinical trial results showing weight loss that surpasses anything currently available. But with that excitement comes a lot of misinformation. Some clinics are already claiming to offer retatrutide, influencers are promoting it on social media, and patients understandably want to know: when can I get it, and is any of what I'm seeing online legitimate?
Here's what you need to know.
What Is Retatrutide and Why Is It Different?
Retatrutide is what scientists call a "triple agonist" because it activates three hormone receptors simultaneously: GLP-1, GIP, and glucagon. If those first two sound familiar, it's because the current generation of weight loss medications already targets them. Semaglutide (Wegovy/Ozempic) works on GLP-1 alone. Tirzepatide (Mounjaro/Zepbound) targets both GLP-1 and GIP. Retatrutide adds glucagon receptor activation, which plays a role in fat breakdown and energy expenditure. Think of it this way: semaglutide pulls one lever to help you lose weight, tirzepatide pulls two, and retatrutide pulls three.
What Do the Clinical Trials Show?
A Phase 2 trial published in The New England Journal of Medicine in 2023 enrolled 338 adults with obesity. Participants on the highest dose (12 mg weekly) lost an average of 24.2% of their body weight over 48 weeks, roughly 58 pounds for someone starting at 240. At 48 weeks, 100% of participants on the 8 mg and 12 mg doses had achieved at least 5% weight loss (Jastreboff et al., NEJM, 2023).
In December 2025, Eli Lilly released Phase 3 results from the TRIUMPH-4 trial that were even more striking: 28.7% average body weight loss (approximately 71 pounds) over 68 weeks. The trial also showed significant improvement in knee osteoarthritis pain, with 1 in 8 patients becoming completely pain-free. A notable new side effect was dysesthesia (skin tingling or sensitivity), reported in about 21% of patients on the highest dose, though generally mild.
| Medication | Receptors | Avg. Weight Loss | Trial Duration | FDA Status |
|---|---|---|---|---|
| Semaglutide | GLP-1 | ~15% | 68 weeks | Approved |
| Tirzepatide | GLP-1 + GIP | ~21% | 72 weeks | Approved |
| Retatrutide | GLP-1 + GIP + GCG | ~28.7% | 68 weeks | Phase 3 Trials |
Note: Numbers reflect clinical trial averages. Semaglutide and tirzepatide data from FDA-approved trials (STEP and SURMOUNT programs). Retatrutide data from investigational trials. Individual results will vary.
When Will Retatrutide Be Available?
As of early 2026, retatrutide is not FDA-approved and cannot be legally prescribed. Seven additional Phase 3 trials are expected to complete throughout 2026. Based on typical regulatory timelines:
Phase 3 completion: Late 2026
FDA submission: Late 2026 to early 2027
Earliest possible FDA approval: Mid-to-late 2027
US commercial launch: Early 2028 (projected)
If the rollout of semaglutide and tirzepatide taught us anything, it's that demand for these medications consistently outpaces supply in the first year or two. Patients should plan accordingly and be skeptical of anyone claiming to offer retatrutide before these milestones are met.
Why Compounded Retatrutide Is Illegal
This is the most important thing to understand: compounded retatrutide is illegal under federal law, and there is no legitimate pathway to compound it.
Compounded semaglutide and tirzepatide are a different story entirely. These are based on FDA-approved active ingredients, and legitimate compounding pharmacies can legally produce customized formulations that are not essentially copies of the brand-name products. When sourced from LegitScript-certified pharmacies and prescribed through a proper medical evaluation, compounded GLP-1 medications are a safe and effective option that many patients rely on today.
Retatrutide is fundamentally different. It has never been FDA-approved for any condition. Under federal law (Sections 503A and 503B of the FDCA), compounding pharmacies can only use components of FDA-approved medications. The FDA has stated this directly: "Retatrutide and cagrilintide cannot be used in compounding under federal law." State regulators, including the Ohio Board of Pharmacy, have echoed this position. No formulation change fixes that. The active ingredient itself is what's prohibited.
Some compounding pharmacies have claimed they can get around this by modifying the formulation, but no modification changes the legal status of retatrutide. Unlike compounded semaglutide or tirzepatide, which are based on approved active ingredients, retatrutide has no approved reference product to work from. The active ingredient itself is what's prohibited, and no formulation adjustment changes that.
The FDA is actively enforcing this. In September 2025, the agency issued more than 40 warning letters to telehealth-based compounding pharmacies, flagging retatrutide products specifically. They've also taken action against products fraudulently labeled "for research purposes" that included human dosing instructions. Internationally, UK law enforcement has seized suspected counterfeit retatrutide alongside fake Mounjaro and Ozempic.
The bottom line: any clinic or website currently selling retatrutide is operating outside the law. The product is unregulated, of unknown quality, and potentially dangerous.
What About Muscle Loss? Retatrutide's Body Composition Advantage
One of the biggest concerns with any weight loss medication is muscle loss. In the STEP-1 trial for semaglutide, nearly 40% of the total weight lost came from lean mass rather than fat. That's a significant amount of muscle to lose alongside fat, and it can slow metabolism, reduce strength, and make long-term weight maintenance harder.
This is one area where retatrutide's triple-agonist mechanism offers a potential advantage. A body composition substudy of the Phase 2 diabetes trial, published in The Lancet Diabetes & Endocrinology in 2025, used DXA scans to measure changes in fat and lean mass in 189 participants. The results showed that retatrutide at the 8 mg dose reduced total body fat mass by 26.1% at 36 weeks, while the proportion of lean mass lost relative to total weight lost was consistent with other weight loss treatments. In other words, despite producing significantly greater overall weight loss than semaglutide or tirzepatide, retatrutide did not cause a disproportionately higher percentage of muscle loss (Coskun et al., Lancet Diabetes Endocrinol, 2025).
Researchers believe the glucagon receptor activation may play a role here. Glucagon promotes fat breakdown and increases energy expenditure, which could help the body preferentially burn fat stores while relatively sparing lean tissue. Preclinical animal models of retatrutide also showed greater reduction in fat mass compared to lean mass, supporting this theory.
You Don't Have to Wait for Retatrutide to Protect Muscle
While retatrutide's body composition data is promising, the reality is that you can address muscle preservation right now by combining current GLP-1 medications with hormone optimization and peptide therapy. This is something we emphasize with every weight loss patient at Affinity Whole Health.
Healthy testosterone levels are one of the most important factors for preserving lean mass during weight loss. Low testosterone leads to muscle loss, fatigue, and slower metabolism, which can undermine your results even on GLP-1 medications. For men or women with testosterone deficiency, combining testosterone therapy with GLP-1 treatment helps prevent muscle loss while losing weight. For women, balanced estrogen and progesterone through hormone replacement therapy supports appetite regulation, fat distribution, and insulin sensitivity during weight loss. We've written about this in detail on our blog: Why GLP-1 Medications Work Better When Hormones Are Balanced.
Peptide therapy is another tool we use to support body composition during weight loss. Sermorelin, a growth hormone-releasing peptide, stimulates your body's natural production of growth hormone and IGF-1, which plays a direct role in preserving lean muscle and supporting fat metabolism. When combined with GLP-1 medications, it helps ensure the weight you're losing comes primarily from fat stores. We cover the science behind this combination in another article: GLP-1 and Sermorelin: The Powerful Combination for Fat Loss.
The point is this: retatrutide may eventually offer improved body composition outcomes built into a single medication. But you don't have to wait years for that. By pairing today's GLP-1 medications with the right hormonal and peptide support, you can achieve similar goals right now.
What Are Your Options Right Now?
You don't have to wait for retatrutide to make meaningful progress. Today's GLP-1 medications already deliver significant results: semaglutide has shown average weight loss of about 15% of body weight, and tirzepatide up to 21%, in major clinical trials. These are safe, effective, and available now.
At Affinity Whole Health, our GLP-1 weight loss programs start at $299/month with everything included: medication, provider consultations, follow-up labs, and free 2-day shipping. Affinity is LegitScript certified and works exclusively with LegitScript-certified compounding pharmacies, so you can be confident in the quality and legitimacy of every medication we prescribe. Every patient works with a dedicated Patient Care Coordinator who guides you from your first lab draw through ongoing treatment optimization. Our medical team, led by Dr. Michael Koehler, MD, takes a comprehensive approach, monitoring your progress, adjusting dosing, and addressing the full picture of metabolic health. For patients also dealing with fatigue or hormonal imbalances, we offer integrated testosterone therapy and hormone replacement therapy programs that complement GLP-1 treatment.
Frequently Asked Questions
Is retatrutide FDA-approved?
No. As of February 2026, it remains in Phase 3 clinical trials. The earliest possible approval is mid-to-late 2027.
Is compounded retatrutide the same as compounded semaglutide?
No. Compounded semaglutide is a legitimate option because semaglutide is an FDA-approved active ingredient that can be legally compounded into customized formulations. Retatrutide has never been approved, so compounding it is categorically prohibited under federal law. These are completely different legal situations.
What should I do if I want to lose weight now?
Current GLP-1 medications are safe, effective, and available today. Clinical trials have shown average weight loss of 15-21% of total body weight. Schedule a free evaluation with Affinity Whole Health to find out if GLP-1 therapy is right for you.
Will Affinity offer retatrutide when it's available?
Affinity Whole Health stays at the forefront of metabolic health treatments. If retatrutide receives FDA approval and meets our clinical standards, we will work to make it available as quickly as possible.
References
1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
2. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. Lancet. 2023;402(10401):529-544. doi:10.1016/S0140-6736(23)01053-X
3. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs. Press Release, December 11, 2025.
4. Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2 trial. Lancet Diabetes Endocrinol. 2025;13(8):674-684. doi:10.1016/S2213-8587(25)00092-0
5. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Accessed February 2026.
Disclaimer: This article is for educational purposes only and is not intended as medical advice, diagnosis, or treatment. Compounded medications from Affinity Whole Health are prepared in FDA-registered compounding facilities and are not FDA-approved drugs. All prescriptions require a provider consultation and lab work. Always consult a licensed healthcare provider before medications or treatment plans. Individual results vary.